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Transforming growth factors (TGFs) 1 are polypeptides that reversibly induce 
certain  nonneoplastic cells to express a  transformed phenotype and to undergo 
anchorage-independent  growth (1, 2).  One of these,TGF-/3, is a  25 kD homodi- 
meric protein  held together  by disulfide bonds.  TGF-/3 has been purified and 
partially sequenced, and its gene has been cloned (3-7).  Using Northern  blots, 
human  TGF-/3 mRNA has  been  identified  in  a  variety of cell  types including 
mitogen-activated  nonadherent  PBMC (7).  TGF-/3 binds  to a  unique  receptor 
and  has no  known  homology to other growth  factors (8,  9).  It was originally 
characterized  by its ability to enhance the growth of normal rat kidney cells in 
soft agar  when present with epidermal  growth factor (EGF) (10).  The  precise 
mechanism  of  this  effect  is  unknown,  although  TGF-/3  has  been  shown  to 
upregulate  EGF  receptors  in  NRK  cells  (11).  Subsequently,  TGF-/3  has  been 
shown to have both growth-enhancing and growth-inhibitory properties, and the 
effect that predominates is dependent upon the particular cell type and the other 
growth factors present (12,  13).  For example, TGF-/3 synergized with platelet- 
derived growth factor to stimulate colony formation by a  3T3 cell line that had 
been  transfected  with  c-myc,  but  inhibited  colony formation  by the  same  cell 
stimulated with EGF (12). 
It has been clearly shown that a  variety of soluble factors can  influence the 
growth  and  effector  function  of murine  and  human  lymphocytes  (14).  The 
present  study examines  the  potential  role  of TGF-/3 in  modulating  human  T 
lymphocyte function. We show that the addition of exogenous TGF-/3 to cultures 
of T  lymphocytes inhibits IL-2-dependent T  cell proliferation, and that activated 
T  cells themselves synthesize and secrete TGF-/3. 
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Journal of Experimental Medicine • Volume 163, May 1986  1037-1050  1037 1038  TRANSFORMING GROWTH  FACTOR  ~  FROM  T  CELLS 
Materials and Methods 
Cell  Preparation.  Human  tonsils  were  obtained  at  tonsillectomy  from  7-20-yr-old 
patients with chronic tonsillitis, and were dispersed into single-cell suspensions.  T  cell- 
enriched (TCE) populations were obtained from tonsillar mononuclear cells by rosetting 
with  2-aminoethylisothiouronium  bromide-treated  sheep erythrocytes (15).  The  TCE 
fractions were further purified by passage over nylon wool columns. The Jurkat cell line, 
a human T  cell leukemia, was kindly donated by Dr. Warner Greene. 
Factors.  TGF-/3 was purified from human platelets as previously described (3).  The 
TGF-13 was homogenous by analysis on SDS-polyacrylamide gels. rIL-2 (lot LP210) was 
kindly provided by Cetus Corp. (Emeryville, CA); it was 96% pure by SDS gel analysis 
and contained <0.04 ng endotoxin per  106 U  (16).  1U IL-2 was defined as the amount 
of IL-2 required  to induce  half-maximal stimulation  of an  IL-2-dependent T  cell  line, 
HT2. 
Culture Conditions.  The TCE fractions were cultured  with Con A  (10 #g/ml; Sigma 
Chemical  Co.,  St.  Louis,  MO)  for  12  h  in  RPMI  1640  plus  10%  FCS  (Dutchland 
Laboratories,  Inc.,  Denver,  PA),  washed  with  RPMI  containing  0.3  M  methyl-a-D- 
mannopyranoside (Calbiochem-Behring Corp., La Jolla, CA), and recultured with various 
concentrations of TGF-/3 in the serum-free medium HB 102 (Hana Media, Berkeley, CA), 
with 25-50 U/ml IL-2. Cells were cultured as 5 x  104 cells/well in 96-well plates (Costar, 
Cambridge, MA) for time periods as indicated. DNA synthesis was measured during the 
last  16  h  of culture.  Cells were pulsed with  1 #Ci of [3H]thymidine (6.7  Ci/mM;  New 
England Nuclear, Boston, MA). Incorporation of [3H]thymidine was measured by standard 
liquid scintillation counting techniques after harvesting by a Skatron harvester (Skatron, 
Inc., Sterling, VA). In other experiments, the TCE fractions were cultured with PHA (2 
#g/ml) in serum-containing media, and transferred to serum-free media at the indicated 
times. 
Immunofluorescence.  Cells (106 per 0.1  ml) to be analyzed for surface immunofluores- 
cence were incubated for 30 min on ice with 5 #l of  either OKT3-FITC (Ortho Diagnostics, 
Inc., Raritan,  N  J), anti-IL-2-R (Becton Dickinson Monoclonal Center,  Mountain  View, 
CA), or anti-transferrin receptor-phycoerythrin (Becton Dickinson Monoclonal Center). 
The cells were then washed twice with HBSS containing 0.1% human serum albumin and 
0.02% azide, and analyzed on a FACS (FACS II.II; Becton Dickinson Immunocytometry 
Systems, Mountain View, CA). Control cells were unstained. For each sample, 20,000 or 
30,000  light-scatter-gated viable cells  were collected.  Fluorescence data  were collected 
with logarithmic ampification, and the specific cell immunofluorescence was expressed as 
channel  numbers  on  a  log  scale.  The  mean  fluorescence  intensity  was  calculated  by 
integrating the fluorescent histograms for the positive cells (compared to control cells). 
Binding Assay.  TGF-B was iodinated  to a  specific activity of 2-4  mCi/nmol using a 
modified chloramine T  method (8). T  cells were incubated for 2 h at 37°C in serum-free 
media to remove bound  endogenous TGF-13. After washing, cells were resuspended  in 
binding buffer (DMEM with 0.1%  BSA,  25 mM Hepes, pH 7.4) containing  1-500 pM 
J25I-TGF-/3 at  10  6 cells per 0.2 ml. Nonspecific binding was determined in the presence 
of 10 nM cold TGF-13. Samples were incubated for 2 h at 25°C in a CO2 atmosphere with 
constant agitation. The cells were then spun down and the supernatants were counted in 
a gamma counter to determine the free ligand concentration. The cell pellet was resus- 
pended  in  binding  buffer and  spun  through  a  silicone oil/paraffin  oil  layer,  and  the 
resulting pellet was counted to determine bound ligand. 
TGF-13 Assays.  Supernatants  to  be assayed for TGF-13 were  obtained  from  T  cells 
cultured from serum-free media in the presence or absence of PHA. After harvesting,  1 
mM PMSF (Pierce Chemical Co.,  Rockford, IL) was added to each supernatant.  Subse- 
quently, the supernatants were dialyzed against  1 M acetic acid, lyophilized to dryness, 
and  reconstituted  in  a  solution  of one part  4  mM  HCI plus  three  parts  DMEM.  The 
bioassay for TGF-/3 depends upon the ability of TGF-t3 to induce anchorage-independent 
growth of normal rat kidney (NRK) fibroblasts grown in the presence of 5 ng/ml EGF in 
soft agar. The soft agar assay was performed as previously described by measuring colony 
formation in 0.3 % agar (10). Colonies were stained after 7 d of incubation, and those >62 KEHRL ET  AL.  1039 
#M in diameter were counted using an Omnicon image analysis system programmed to 
count a 5-cm 2 area ofa 35-mm-diam plate. 
The radioreceptor assay for TGF-13, a competitive binding assay that uses A549 cells, 
was performed as previously described (8). A549 cells were incubated with I~SI-TGF-/3 
for 2 h at 25°C in 5% CO2 in the presence of various dilutions of the test supernatant. 
After incubation, the cells were washed four times with cold HBSS (Gibco Laboratories, 
Grand Island, NY) containing 0.1% BSA. The cells were solubilized with 0.6 ml Triton 
solution (20 mM Hepes, 2% Triton X-100,  10% glycerol, 0.01% BSA, pH 7.4) by a 20- 
min incubation at room temperature, and counted on a gamma counter. A TGF-13 standard 
curve was constructed using serial dilutions of a known amount of TGF-13. 
Northern Blots.  Total RNA was isolated from T  cells using a guanidine thiocynanate 
method. The purified total RNA was electrophoresed in agarose-formaldehyde gels and 
transferred to either nitrocellulose (Schliecher and Schuell, Keene, NH) or Gene Screen 
II (New  England Nuclear). The size-fractionated RNA was probed using a  3~P-labelled 
Eco R1  insert from ~,/3C1 under high stringency conditions (7). As previously reported 
(7), the TGF-13 probe recognized an mRNA of ~2.5 kb. 
Results 
TGF-t3 Suppresses IL-2-dependent T Cell Proliferation and Partially Inhibits IL-2- 
R and Transferrin Receptor Expression.  Since serum is a source of TGF-/3 and a 
variety of binding  proteins  for  TGF-/3  could be  present  in  serum,  all  of the 
experiments  examining  the  effects of TGF-13  were  performed  in  serum-free 
media.  T  cells  were  stimulated  with  Con  A  for  8-12  h  in  serum-containing 
media, washed, and recultured in serum-free media. This duration of stimulation 
is sufficient for cellular activation and IL-2-R expression, but not for subsequent 
progression into S phase unless exogenous IL-2 is present (17,  18).  Fig.  1 (top) 
shows the  effect of TGF-13  on  DNA  synthesis by Con A-activated tonsillar T 
lymphocytes that were cultured in the presence of IL-2. Optimal concentrations 
of TGF-/3 suppressed DNA synthesis by 60-80%. This degree of suppression was 
present 3, 4, and 5 d after the addition of IL-2 and TGF-/3 (Fig. 1, bottom). TGF- 
/3 was not toxic to the T  cells, as judged by trypan blue dye exclusion. 
Additionally,  the  effects  of  2  ng/ml  of TGF-/3  on  IL-2-dependent  T  cell 
proliferation were examined as a function of IL-2 concentrations (Table I). TGF- 
13 was most suppressive at the lower IL-2 concentrations. At higher IL-2 concen- 
trations  (100  and  300  U/ml),  the  degree  of suppression  decreased,  although 
some suppression was present even at 300 U/ml. The degree of suppression was 
greater at day 5 than at day 3. Thus, by regulating the amount of IL-2 and TGF- 
/3 present, the amount of T  cell proliferation can be regulated. 
The interaction of IL-2 with its receptor on T  cells has been shown (19) to be 
of primary importance in T  cell growth, and satisfies the criteria for an autocrine 
system. One of the consequences of this interaction is an upregulation in cell- 
surface membrane IL-2-R (20,  21).  IL-2 has also been shown (22-24)  to be an 
important signal in the upregulation of another receptor, the transferrin recep- 
tor, which is thought to be important in cellular growth and is found on rapidly 
dividing cells. A  potential mechanism whereby TGF-/3 might inhibit the growth 
of T  cells is by interfering with the normal expression of either of these receptors. 
In  Fig.  2,  the  effects  of TGF-/3  on  IL-2  and  transferrin  receptor  levels  are 
examined using immunofluorescence with a mAb against the transferrin receptor 
and an anti-IL-2-R mAb.  Exposure of previously activated T  cells to IL-2 for 
16 h  was sufficient to result in enhanced expression of both the IL-2-R and the 1040  TRANSFORMING  GROWTH  FACTOR  /3  FROM  T  CELLS 
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FIC, URE  1.  Suppression of T cell DNA synthesis by TGF-/3. The TCE fractions were cultured 
with Con A, 10 I~g/ml, for 12 h in RPMI 1640 plus 10% FCS; washed with RPMI containing 
0.3 M methyl-a-D-mannopyranoside; and recultured with IL-2 and various concentrations of 
TGF-/3 in HB102 media. Data in the upper panel are the mean _SEM for four experiments 
that were harvested on day 3 after a  16-h  pulse with [SH]thymidine. Percent suppression  is 
calculated as (1 -  [cpm in presence of TGF-/3] -  [background])/([cpm in absence of TGF-13] - 
[background]). Data in the lower panel are [SH]thymidine incorporation from one experiment 
harvested on different days (days  3, 4, and 5). 
TABLE  I 
Effect of TGF-[3 on IL-2-dependent T Cell Proliferation as a 
Function of lL-2 Concentration 
IL-2 
(U/ml) 
[nH]Thymidine incorpora- 
tion day 3 (cpm/105 cells) 
[SH]Thymidine incorpora- 
tion day 5 (cpm/10  ~ cells) 
No TGF-/3  TGF-/3*  No TGF-/3  TGF-/3* 
0  7,302  3,721  9,175  1,523 
3  10,531  3,954  9,581  1,464 
10  34,241  11,474  22,440  3,942 
30  82,930  45,411  79,251  9,620 
100  92,766  79,442  170,323  96,688 
300  102,645  88,109  189,512  161,306 
T  cells were  activated  with  Con  A  and  cultured  in  the  presence  or 
absence  of IL-2.  [SHlThymidine  incorporation  was  measured  as  de- 
scribed in the Materials and Methods, 
* TGF-/3 present at 2 ng/ml. 
transferrin  receptor.  If TGF-~  was  present  in  the culture  together  with  the  IL- 
2, the increase in density of both receptors  was ablated.  Additionally, the presence 
of TGF-/3 in culture  reduced  the number  of IL-2R ÷ cells from  99 to 76%.  TGF- KEHRL  ET  AL.  1041 
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FIGURE 2.  Regulation of the IL-2-R and transferrin receptors on human T cells by IL-2 and 
TGF-fl. T cells were purified from tonsillar mononuclear cells and activated with 2 pg/ml of 
PHA for 4 d in RPMI with 10% FCS. The cells were harvested and replated in 24-well Costar 
plates at 106 cells/well in HB102 media in the presence of media alone, 25 p/ml of IL-2, or 2 
ng/ml TGF-fl plus IL-2. 16 h later, the cells were harvested and immunofluorescently stained 
with an anti-lL-2-R mAb, and an anti-transferrin receptor mAb. The cells were analyzed 
with a FACS. The mean fluorescent  intensity (MFI) of the positive cells is indicated in the 
upper right portion of each FACS pattern.  The IL-2-R is referred to as Tac. 
/3 did not modulate T3-R expression (data not shown).  Thus, a  possible mecha- 
nism  whereby TGF-/3 suppresses T  cell proliferation  is by interfering  with  the 
normal  regulation  of  IL-2-R.  The  diminished  expression  of  the  transferrin 
receptor may be a secondary effect related to the effects of TGF-fl on the IL-2- 
R. 
T  Cell Activation Results in  Upregulation of TGF-fl-R.  A  binding  assay using 
]25I-iabeled TGF-fl has been previously developed and used to demonstrate the 
presence of TGF-/3 receptors on a  variety of cell lines (8,  9). We examined the 
expression  of  TGF-fl  receptors  on  unstimulated  and  activated  T  cells.  The 
unstimulated  T  cells had  low numbers  of high-affinity TGF-fl-R.  When  the  T 
cells were cultured  in  the presence of PHA for 36  h,  the  number of TGF-fl-R 
per cell increased approximately sixfold compared to cells cultured in the absence 
of PHA (Fig.  3). The affinity of the TGF-fl-R for its ligand was not significantly 
changed  when  the  T  lymphocytes  were  stimulated.  Although  the  number  of 
TGF-fl-R present on activated T  cells is less than almost all the cell lines previously 
tested, the affinity of the receptor on T  cells is higher by 5-10-fold (8,  9).  The 
effect of IL-2 on TGF-fl binding was also examined.  T  cells were activated for 
12 h  with Con A, washed with a-methyl mannoside, and recultured  for 24 h  in 
the presence or absence of IL-2. The presence of IL-2 did not alter the number 
or  the affinity of the  TGF-fl-R present  (data not  shown).  Thus,  resting T  cells 
express low numbers of TGF-fl-R, and cellular activation results in a  substantial 
increase in their number. 
T Cell Activation Results in Appearance of TGF-fl mRNA in T Cells and Increased 1042  TRANSFORMING GROWTH  FACTOR /3  FROM T  CELLS 
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FIGtJRE 3.  T cell activation results in an increase in the number of TGF-/3 binding sites per 
cell. Typical  curves for the specific  binding of ~SI-TGF-/3  to activated  and unactivated  tonsillar 
T lymphocytes.  Scatchard analysis of the binding curves revealed the indicated affinity and 
number of binding sites. Unstimulated (O), Kd = 2 pM; sites/cell, 58. PHA-stimulated  (O), Kd 
= 5.1; sites/cell, 380. 1 pM of TGF-/3 corresponds to 25 pg/ml. 
Production of TGF-13 in Culture Supernatants.  The previous data showed that T 
cells have receptors for TGF-/3, that exogenous TGF-/3 can modulate T  cell DNA 
synthesis, and that exogenous TGF-/3 interferes with the normal regulation of 
IL-2  and  transferrin  receptors.  The  likelihood  that  TGF-/3  is  an  important 
regulator of T  cell function would be considerably enhanced if T  cells themselves 
made TGF-J3. Previous experiments (7) showed the induction of TGF-/3 mRNA 
in mitogen-stimulated PBMC. To ascertain whether stimulated T  cells actively 
secreted  TGF-/3,  we  determined  whether  supernatants  conditioned  by  either 
unstimulated or stimulated T  cells contained TGF-/3 biologic activity. We also 
examined purified T  cells for the presence of TGF-~ mRNA and examined the 
temporal relationship between induction of TGF-/3 mRNA and the secretion of 
TGF-/3 by activated T  cells. 
To  show TGF-/3 biologic activity in  conditioned media,  T  cells were  either 
cultured  in  serum-free  media  in  the presence  or absence  of PHA,  or initially 
cultured  in  serum-containing media  in  the presence  or absence  of PHA,  and 
after  extensive  washing,  transferred  to  serum-free  conditions.  The  collected 
supernatants were assayed for TGF-/3 biologic activity using a  soft agar assay. 
This assay relies upon the ability of TGF-/3 to enhance the growth of NRK cells 
in agar in the presence of EGF (10). Supernatants conditioned by unactivated T 
cells had low levels of TGF-/3-1ike biologic activity (0.6-1.6  pM), while superna- 
rants from PHA-activated T  cells had levels 10-50-fold higher (20-74 pM, Table 
lI). To confirm that the TGF-/3 like biologic activity was indeed due to TGF-/3, 
the superantants were also assayed in a competitive radioreceptor assay (8).  This 
assay detects TGF-/3 in an unknown sample by its ability to inhibit the binding of 
radiolabeled TGF-/3 to a cell line that expresses large numbers of TGF-/3-R. The 
results from the radioreceptor assay strongly correlated with the results from the 
soft agar assay, and confirms the presence of TGF-/3 in the T  cell supernatants 
(Table II). We have also tested supernatants conditioned by several different T 
cell lines and found TGF-/3 present in them. Table II shows that the human T 
cell leukemia cell line, Jurkat, constitutively secretes a moderate amount of TGF- 
To confirm the presence of TGF-/3 mRNA in activated T  lymphocytes, and to 
examine the time course of expression of TGF-/3 mRNA, human tonsillar T  cells KEHRL  ET  AL. 
TABLE  II 
TGF-13 Production by Human T Lymphocytes 
Exp.  Sample  Soft agar assay  Binding assay 
(pM)  (pM) 
1  Unstimulated  2.3  4,9 
PHA  23  (10)*  21  (4.3) 
2  Unstimulated  1.6  0.62 
PHA  74  (46)  32  (56) 
3  Jurkat  14  26 
In the first experiment, tonsillar T cells were cultured for 4 d in serum- 
free  media at a concentration of 2 x  l0  s cells/ml in the presence  or 
absence  of  PHA.  In  the  second  experiment, tonsillar  T  cells were 
cultured in serum containing media  in the presence  or absence  of 2 
#g/ml of PHA. After 48 h, the cells were harvested, washed three times, 
and recultured in serum-free media for 4 d.  In the third experiment, 
Jurkat cells were  cultured in serum-free  media  for  2  d  at an initial 
concentration of 2 x  106 cells/ml. 
* Number in parentheses  is the fold stimulation. 
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FIGURE 4.  TGF-13  mRNA is rapidly  induced in stimulated  T  cells. Northern blot of RNA 
obtained at various time intervals after stimulation with 2 #g/ml of PHA in serum-containing 
media. The time 0 point was cultured for 2 h in the absence of PHA.  RNA was extracted 
from  10  8 cells for each time point. 15 #g of total cytoplasmic RNA was loaded per lane. 
were  cultured  with  PHA  for  various  periods  of time.  Total  RNA  from  each 
group of cells was  isolated and analyzed using Northern  blots with the  TGF-/5 
cDNA as a  hybridization probe. Fig. 4  shows the induction of TGF-/3 mRNA  in 
T  cells  at  various  times  after  stimulation.  Unstimulated T  cells  had  low  to 
undetectable levels of TGF-/5 mRNA,  while  PHA-activated T  cells  expressed 
substantial levels of TGF-/5 mRNA.  The  message appeared rapidly after stimu- 
lation, and thereafter the level of message was relatively constant. In contrast to 
the  rapid  induction and plateauing of TGF-/3 mRNA,  the  rate  of secretion of 
TGF-/3 into culture supernatants gradually increased during the culture and did 
not reach maximal levels until 72-96  h  after stimulation (Fig. 5). 
Human  T  cells can be subdivided into two major subsets on the basis of the 
expression of either the  T4  or  the  T8  surface marker.  We examined whether 1044  TRANSFORMING  GROWTH  FACTOR  /3  FROM  T  CELLS 
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FIGURE 5.  Kinetic of TGF-13 production by activated T  lymphocytes. Tonsillar T  lympho- 
cytes were activated with PHA (2 #g/ml) in the presence of serum.  24 h  before termination 
of the culture,  the cells were  harvested, washed extensively, then recultured  in serum-free 
media.  At the end of the culture period,  the supernatants were assayed for TGF-13 activity 
using the soft agar assay. For the 0-24 h points, the cells were cultured for 2 h in the presence 
of serum, washed, and recultured in serum-free media in the presence or absence of PHA for 
24  h.  The  unstimulated culture  contained 4  pg/ml  of TGF-/5.  (0),  TGF-/3 secreted  in  the 
previous 24 h  (left y axis); (0), calculated accumulation of TGF-13 to that time point (right y 
axis). 
FIGURE 6.  TGF-/3 mRNA  is present in both T4 and T8  lymphocytes.  Peripheral blood T 
lymphocytes were separated into a T4 and T8 population using an affinity rosetting technique. 
Each fraction was >90% pure, as judged by immunofluorescence. The T4 and T8 populations 
(5.0 x  107 cells for each fraction) were stimulated with 2 #g/ml of PHA in serum containing 
media for 24 h, and after extraction of the RNA from each fraction, they were analyzed for 
the presence of TGF-/3 mRNA. 
T4  or T8  lymphocytes  preferentially expressed TGF-t3  message.  T  cells were 
separated into T4 and T8  fractions using immune rosetting, and each fraction 
was stimulated with PHA for 24 h. Total RNA from each fraction was purified, 
and  a  Northern  blot  was  performed  (Fig.  6).  Although  both  the  T4  and  T8 
subsets  were  induced  to  express  TGF-/3  mRNA,  the  T4  subset  expressed  a 
slightly greater amount.  Thus,  both activated  T4 and T8  cells contain  mRNA 
for TGF-/3,  and significant quantities of TGF-/3 are secreted by activated T  cells. KEHRL  ET  AL.  1045 
Discussion 
This report examines the effect of TGF-/3 on human T  cell proliferation and 
proposes that TGF-/3 production by T  lymphocytes may be important in lympho- 
cyte immunoregulation and T  cell interactions with other cell types. We showed 
that T  lymphocytes have receptors for TGF-~, which are upregulated after T 
cell activation, that the addition of exogenous TGF-/3 impaires IL-2-dependent 
T  cell proliferation, and that it inhibits IL-2-induced upregulation of the IL-2-R 
and the transferrin receptor. Additionally, we confirmed the presence of TGF- 
13 mRNA in  activated T  cells, and determined the kinetics of TGF-~ mRNA 
induction after T  cell activation.  Finally, we have shown that TGF-/~  biologic 
activity is present in culture supernatants conditioned by human T  cells, and that 
PHA activation results in a  10-46-fold increase in TGF-/3 production. 
We think it is unlikely that the TGF-/~ detected in the conditioned supernatants 
is related to a cell type other than T  cells. The experiments described here used 
T cells purified from tonsillar mononuclear cells. These preparations were <0.5% 
esterase positive. Although there is sufficient accessory cell function to induce a 
PHA response,  there are numerically very few monocytes present.  Thus,  it is 
unlikely that  PHA would stimulate the few remaining accessory cells to make 
significant levels of TGF-/3 mRNA and to secrete the quantities of TGF-/3 we 
have detected in the conditioned supernatants. Also arguing that T  cells are a 
source of TGF-~ is the production of TGF-/~ by a  human T  cell leukemia cell 
line. 
The  means by which resting T  cells are activated and induced to  undergo 
clonal  expansion  has  been  intensively studied.  The  major  pathway of T  cell 
activation occurs via the interaction of appropriately processed and presented 
antigen with the T cell receptor (25-27). This interaction results in the expression 
of IL-2-R,  and  the  synthesis and  secretion  of IL-2  (28,  29).  Once a  critical 
number of high-affinity IL-2-R  on  the T  cell  membrane have bound  ligand, 
DNA synthesis and cell division occurs. Additionally, the interaction of IL-2 with 
its receptor is a positive feedback signal for the cell to further increase its number 
of IL-2-R (20, 21, 30). Whether predominantly low-affinity IL-2-R or both high- 
and low-affinity IL-2-R are increased by this interaction is controversial (30, 31). 
Once T  cell mitosis occurs, T  cells continue to express IL-2-R and to proliferate 
in response to IL-2.  However, even in the presence of exogenous IL-2,  the T 
cell proliferation gradually decreases. Accompanying this decrease in prolifera- 
tion is a decrease in IL-2-R expression (32). In this pathway of T  cell activation 
~nd proliferation, the major regulatory signals are antigen in conjunction with 
Ia,  IL-2, and  IL-2-R expression. The observations reported here suggest that 
TGF-/3 may also be an important physiologic regulator of T  cell growth. 
The evidence supporting a role for TGF-/3 in the regulation of T  cell growth 
includes the demonstration that the addition of exogenous TGF-13 to cultures 
inhibits  IL-2-dependent T  cell  proliferation  and  blocks  IL-2-induced  IL-2-R 
upregulation, that receptor levels for TGF-/3 are dependent upon the state of 
cellular activation, that T  cells upon activation produce mRNA for TGF-13, and 
that TGF-/3 is secreted by PHA-activated T  cells in concentrations in the range 
of those capable of inhibiting T  cell proliferation. 
The early synthesis of TGF-/3 mRNA at a time when the cells are being induced 1046  TRANSFORMING  GROWTH  FACTOR  /3  FROM  T  CELLS 
to  proliferate appears  to  be  contradictory to  this  hypothesis that  TGF-13 is  a 
growth  inhibitor.  However,  despite  the  early appearance  of TGF-13 mRNA, 
significant quantities of the processed TGF-/3 protein were not secreted until 2- 
4  d  later  in  culture.  Thus,  a  prolonged  interval  sufficient  for  the  gradual 
accumulation of TGF-/3 may be required to trigger an inhibitory signal. Further- 
more,  the  inhibitory  effect  of exogenous  TGF-/3  on  IL-2-dependent  T  cell 
proliferation can be partially overcome by the addition of a higher concentration 
of  IL-2.  This  suggests  that  the  balance  between  IL-2  and  TGF-I3  may  be 
important in regulating T  cell proliferation. 
It  has  been  shown  (33)  that  TGF-13 can  be  secreted  by  certain  cells  in  a 
biologically inert form that is unmasked by acid treatment of the culture media. 
The platelet-derived TGF-/3 used in  the functional studies described here has 
been acid treated dui-ing the purification process. This leaves open the possibility 
that lymphocyte-derived TGF-/3 does not impart an inhibitory signal unless it is 
activated in some manner. Experiments are in progress to examine this possibility. 
There is a precedent for TGF-/3 being an autocrine growth inhibitor.  In this 
regard, TGF-I3 and a growth inhibitor from green monkey kidney cells (BSC-1) 
have been shown to have nearly identical biologic activity, and to compete for 
binding to the same membrane receptor (13, 34). The BSC-1  cells produce the 
inhibitor  when arrested at  saturation  density.  The growth inhibitor has been 
purified from media conditioned by density-arrested cells, and has been shown 
to inhibit the proliferation of the same cells at a low cell density (34). 
The production of TGF-13 by T  lymphocytes may not only be important in the 
regulation of lymphocyte function, but also may be important in the interaction 
of T cells with other cell types. For example, TGF-13 has been shown to accelerate 
wound healing (35). Collagen deposition in a healing wound generally begins 5- 
7 d  after the injury (36).  This is preceded by an influx of mononuclear cells. 
Although the macrophage is the predominant cell type in this cellular infiltrate, 
lymphoid cells are also present (36).  T  cell production of lymphokines such as 
TGF-B during this early phase of wound healing may be an important signal for 
fibroblasts to synthesize collagen (37,  38).  Whether macrophages also produce 
TGF-13 is currently being investigated. 
While a resolving acute inflammatory response such as a healing wound results 
in minimal fibrosis, chronic inflammation can cause considerable scarring with 
subsequent tissue deformation. Areas of chronic inflammations are characterized 
by a mononuclear cell infiltrate, fibroblast proliferation, and fibroblast collagen 
production. The continued production of TGF-/3 by activated T  cells in these 
inflammatory sites may be important in maintaining fibroblast collagen synthesis. 
Furthermore, aberrant TGF-/3 production by T  iymphocytes may be important 
in certain diseases that are characterized by excessive collagen production. 
Conversely, TGF-13 production by other cells may influence immune function. 
The exposure of T  cells to large amounts of TGF-/3 would, very likely, severely 
limit normal T  cell function. Certain  tumor and virally transformed cell lines 
have been shown (2)  to produce large amounts of TGF-13. The production of 
TGF-13 by tumors in  vivo could enhance a  tumor's ability to  escape immune- 
mediated destruction. In addition to the effects of TGF-13 on T  cell function, we 
have also shown that TGF-/3 inhibits NK activity (39) and B cell function (Kehrl, KEHRL  ET  AL.  t047 
J.  H.,  A.  B.  Roberts,  L.  M.  Wakefield,  S. Jakowlew,  M.  B.  Sporn,  and  A.  S. 
Fauci. TGF-3 is an important immunomodulatory protein for human B lympho- 
cytes, manuscript in preparation). 
Thus, TGF-3 production by T  lymphocytes may have two roles in inflamma- 
tory foci: the first to limit T  and B cell clonal expression and subsequent effector 
function by a feedback mechanism, and second, to stimulate fibroblast prolifer- 
ation and collagen production.  By limiting T  cell clonal expansion and presum- 
ably further T  cell TGF-3 secretion, the production of TGF-3 by T  lymphocytes 
may be an important signal in the regulation of inflammation. 
Summary 
This study examines the potential role of transforming growth factor 3 (TGF- 
3)  in  the  regulation  of human  T  lymphocyte proliferation,  and  proposes that 
TGF-3  is  an  important  autoregulatory  lymphokine  that  limits  T  lymphocyte 
clonal expansion, and that TGF-3 production by T  lymphocytes is important in 
T  cell  interactions  with  other  cell  types.  TGF-3  was  shown  to  inhibit  IL-2- 
dependent T  cell proliferation. The addition of picograms amounts of TGF-3 to 
cultures of IL-2-stimulated human T  lymphocytes suppressed DNA synthesis by 
60-80%.  A potential  mechanism  of this inhibition  was found. TGF-3 inhibited 
IL-2-induced upregulation  of the IL-2 and transferrin  receptors.  Specific high- 
affinity receptors for TGF-3 were found both on resting and activated T  cells. 
Cellular activation was shown to result in a five- to sixfold increase in the number 
of TGF-3 receptors on a  per cell basis, without a  change in the affinity of the 
receptor. Finally, the observations that activated T  cells produce TGF-3 mRNA 
and  that  TGF-3  biologic  activity  is  present  in  supernatants  conditioned  by 
activated T  cells is strong evidence that T  cells themselves are a source of TGF- 
3.  Resting  T  cells  were  found  to  have  low  to  undetectable  levels  of TGF-3 
mRNA,  while  PHA  activation  resulted  in  a  rapid  increase  in  TGF-3  mRNA 
levels (within 2 h). Both T4 and T8 lympocytes were found to make mRNA for 
TGF-3 upon activation.  Using both a soft agar assay and a competitive binding 
assay, TGF-3 biologic activity was found in supernatants conditioned by T  cells; 
T  cell activation resulted in a  10-50-fold increase in TGF-3 production.  Thus, 
TGF-3  may  be  an  important  antigen-nonspecific  regulator  of human  T  cell 
proliferation,  and  important  in  T  cell  interaction  with  other cell  types whose 
cellular functions are modulated by TGF-3. 
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